期刊
BRITISH JOURNAL OF CANCER
卷 100, 期 11, 页码 1824-1831出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.bjc.6605086
关键词
infertility; clomiphene; gonadotrophins; ovarian stimulation; mortality
类别
资金
- Cancer Research UK [C1388/A2480]
- 5-year programme [C150/A5660]
To assess long-term health effects of ovarian-stimulation drugs we followed-up for over 20 years a British cohort of 7355 women with ovulatory disorders, 43% of whom were prescribed ovarian-stimulation drugs, and identified a total of 274 deaths and 367 incident cancers. Relative to the general population, the cohort experienced lower mortality from most causes, including from all neoplasms combined, and lower incidence of cervical cancer, but higher incidence of cancers of the breast (relative risk: 1.13; 95% CI 0.97, 1.30) and corpus uteri (2.02; 1.37, 2.87). There were, however, no significant differences in the risk of cancers of the breast, corpus uteri, ovary, or of any other site, between women who had been prescribed ovarian-stimulation drugs and those who had not. Further analyses by type of drug and dose revealed a dose-response gradient in the risk of cancer of the corpus uteri (P for linear trend = 0.03), with women given >= 2250 mg of clomiphene having a 2.6-fold (2.62; 0.94, 6.82) increase in risk relative to those who were not treated. These findings do not support strong associations between ovulation-stimulation drugs and cancer risks, but they indicate the need for continued monitoring to establish whether risks are elevated in certain subgroups of users. British Journal of Cancer (2009) 100, 1824-1831. doi: 10.1038/sj.bjc.6605086 www.bjcancer.com Published online 12 May 2009 (C) 2009 Cancer Research UK
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据